Sprint Bioscience AB (publ) announced that the company in its collaboration with Associate Professor Julian Walfridsson on novel target proteins in acute myeloid leukemia (AML) has identified several new AML target protein starting points for further possible development using Sprint Bioscience's fragment-based drug discovery (FBDD) platform. In a very short time, the target discovery approach that is applied in the collaboration has been validated as the first novel target proteins have been confirmed in cellular models of AML. Furthermore, by eliminating target proteins with potential safety risks early on in the process, the collaboration can deliver drug discovery programs with improved safety profiles.

The feasibility for further development in Sprint Bioscience's FBDD platform will be evaluated prior to incorporating them in the Sprint Bioscience pipeline. The collaboration is aiming at identifying novel target proteins for AML treatments and applies an innovative combination of bioinformatics, CRISPR screening and safety assessment.